- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: ALD-518 | ALD518 | BMS-945429
Compound class: Antibody
Comment: Clazakizumab is an investigational, aglycosylated, humanized (from a rabbit parental antibody) monoclonal antibody targeting interleukin-6, with anti-inflammatory potential .
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. BLAST peptide sequence analysis reveals identical matches with peptides claimed in patent US8062864 . Results presented in the patent show that the preferred antibodies block interaction of IL-6 with the IL-6 receptor, but no precise binding affinity data is provided.
|No information available.|
|Summary of Clinical Use|
|Phase 2 clinical trials in patients with active rheumatoid arthritis (NCT01373151, results reported in ), psoriatic arthritis (NCT01490450, results in ), cachexia resulting from non-small cell lung cancer [1,4], acute graft versus host disease (GvHD) and oral mucositis caused by head and neck cancer have been completed. Click here to link to ClinicalTrials.gov's list of clazakizumab (ALD518 and BMS-945429) trials.
SARS-CoV-2 and COVID-19: Clazakizumab has been entered into clinical trials in patients with COVID-19, with a particular focus on assessing its efficacy in those with life-threatening hyperinflammation.
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT01373151||Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate||Phase 2 Interventional||Vitaeris INC|
|NCT01490450||Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy||Phase 2 Interventional||Vitaeris INC|
|NCT04381052||Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection||Phase 2 Interventional||Columbia University|
|NCT04363502||Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection||Phase 2 Interventional||Johns Hopkins University|
|NCT04351724||Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)||Phase 2/Phase 3 Interventional||Medical University of Vienna|
|NCT04348500||Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease||Phase 2 Interventional||Cedars-Sinai Medical Center|
|NCT04343989||A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection||Phase 2 Interventional||NYU Langone Health|